Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorHashimoto, Akiko Soneda
dc.contributor.authorYu, Jianshi
dc.contributor.authorWilliams, Christina
dc.contributor.authorZueckert-Gaudenz, Karin
dc.contributor.authorVarshosaz, Parisa
dc.contributor.authorZhao, Ruonan
dc.contributor.authorValenzuela, Irene
dc.contributor.authorMARTÍNEZ GIL, NÚRIA
dc.contributor.authorCosta Roger, Mar
dc.date.accessioned2025-10-14T09:50:23Z
dc.date.available2025-10-14T09:50:23Z
dc.date.issued2025
dc.identifier.citationHashimoto AS, Yu J, Williams C, Gaudenz K, Varshosaz P, Zhao R, et al. Identification and characterization of short-chain dehydrogenase/reductase 3 (DHRS3) deficiency, a retinoic acid embryopathy of humans. Genet Med Open. 2025;3:103427.
dc.identifier.issn2949-7744
dc.identifier.urihttp://hdl.handle.net/11351/13848
dc.descriptionCraniosynostosis; Noncoding variant; Retinoic acid
dc.description.abstractPurpose: Signaling by the morphogen all-trans retinoic acid (RA) is critical for embryonic development, during which its tissue concentration must be tightly regulated. We investigated 8 sibships (12 individuals) segregating 5 different homozygous variants of dehydrogenase/reductase 3 ( DHRS3), which encodes an embryonically expressed enzyme (short-chain dehydrogenase/reductase 3; also termed SDR16C1) that catalyzes the reduction of retinaldehyde to retinol, limiting excessive RA synthesis. Methods: We assessed variant pathogenicity using comparative phenotypic and bioinformatic analysis, quantification of DHRS3 expression, and measurement of plasma retinoid metabolites. Results: Five homozygotes from 3 families (1 family segregating a deletion of the promoter and 5'-untranslated region of DHRS3, the other 2 a missense variant p.(Val171Met)), manifested a congruent phenotype, including coronal craniosynostosis, dysmorphic facial features, congenital heart disease (4/5 individuals), and scoliosis (5/5 individuals). Transcription of DHRS3 in whole blood cells from 2 homozygotes for the promoter/5'-untranslated region deletion was 90% to 98% reduced. Cells transfected with a DHRS3-Val171Met construct exhibited reduced retinaldehyde reduction capacity compared with wild-type, yielding reduced retinol and elevated RA; correspondingly, plasma from homozygous patients had significantly reduced retinol and elevated RA (exceeding the normal range), compared with controls and heterozygous relatives. Three additional homozygous missense variants of DHRS3 (p.(Val110Ile), p.(Gly115Asp), and p.(Glu244Gln)) were shown to reduce catalytic activity in vitro and/or in vivo but were associated with normal or different phenotypes that did not meet the threshold to assign likely pathogenicity. Conclusion: We define a novel developmental syndrome associated with biallelic hypomorphic variants in DHRS3; a careful assessment of individual variants is required to establish a causal link to phenotype.
dc.language.isoeng
dc.publisherElsevier
dc.relation.ispartofseriesGenetics in Medicine Open;3
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectTretinoïna
dc.subjectVitamina A
dc.subjectMalformacions
dc.subjectEmbriologia
dc.subject.meshEmbryonic Development
dc.subject.meshVitamin A
dc.subject.meshCongenital Abnormalities
dc.subject.meshTretinoin
dc.titleIdentification and characterization of short-chain dehydrogenase/reductase 3 (DHRS3) deficiency, a retinoic acid embryopathy of humans
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1016/j.gimo.2025.103427
dc.subject.decsdesarrollo embrionario
dc.subject.decsvitamina A
dc.subject.decsanomalías congénitas
dc.subject.decstretinoina
dc.relation.publishversionhttps://doi.org/10.1016/j.gimo.2025.103427
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Hashimoto AS] Clinical Genetics Group, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom. [Yu J, Williams C] Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy, Baltimore, MD. [Gaudenz K, Zhao R] Stowers Institute for Medical Research, Kansas City, MO. [Varshosaz P] Medical Sciences Division, Northern Ontario School of Medicine University, Sudbury, ON, Canada. [Valenzuela Palafoll MI, Martínez-Gil N, Costa-Roger M] Àrea de Genètica Clínica i Molecular, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Grup de Recerca de Medicina Genètica, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain
dc.identifier.pmid40519748
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record